Comments and Letters

  • Comment Letter on Palmetto LCD for Molecular Diagnostic Tests

    December 02, 2011
        December 2, 2011   Dr. Elaine Jeter, Medical Director Mr. Michael Barlow, Vice President Palmetto GBA (J1 MAC) P.O. Box 100190, AG 300 Columbia, South Carolina 29202-3190   RE: Palmetto GBA Draft Local Coverage Determination (LCD) for Molecular Diagnostic Tests (MDT) (DL 32288)   Dear Dr. Jeter and Mr. Barlow:   The American Clinical Laboratory Association (“ACLA”) hereby submits comments on PalmettoContinue Reading »...
  • Comments on HHS Proposed Rule on Patient Access to Test Results

    November 14, 2011
      November 14, 2011   Centers for Medicare & Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building 200 Independence Avenue S.W. Washington, DC 20201   RE:      BIN 0938-AQ38; CLIA Program and HIPAA Privacy Rule; Patients’ Access to Test Reports; Proposed Rule Dear Sir or Madam,   The American Clinical Laboratory Association (“ACLA”) appreciates the opportunity to comment onContinue Reading »...
  • Letter On Implementation of Meaningful Use 2 and re-implementation of Meaningful Use 3

    October 31, 2011
    October 31, 2011   Farzad Mostashari, MD, ScM Office of the National Coordinator for Health Information Technology U.S. Department of Health and Human Services 200 Independence Avenue S.W. Suite 729-D Washington, D.C. 20201   RE: Implementation of Meaningful Use 2 and re-implementation of Meaningful Use 3   Dear Dr. Mostashari,   The American Clinical Laboratory Association (ACLA) is an association representing clinical laboratories throughout theContinue Reading »...
  • Letter to Rep. Burgess Regarding the Modernizing Laboratory Test Standards for Patients Act

    October 14, 2011
        October 14, 2011   The Honorable Michael Burgess, MD United States House of Representatives 2241 Rayburn House Office Building Washington, D.C. 20515   Dear Congressman Burgess:   The American Clinical Laboratory Association (ACLA) is extremely pleased to offer our full and strong support for H.R. 3207 the Modernizing Laboratory Test Standards for Patients Act. This Bill is in lock‐step with the needContinue Reading »...
  • Comments to NIH Regarding Practical Utility of the Proposed Collection of Information for the Genetic Testing Registry

    September 26, 2011
        September 26, 2011  Genetic Testing Registry Staff National Institutes of Health Re:      Comments on the practical utility of the proposed collection of information for the Genetic Testing Registry The American Clinical Laboratory Association (ACLA) appreciates the opportunity to provide additional comments on the practical utility of the proposed collection of information for the Genetic Testing Registry (GTR). ACLA represents national, regional, andContinue Reading »...
  • Letter to HHS Regarding Nationwide Electronic Health Information Exchange

    September 23, 2011
      September 23, 2011 Department of Health & Human Services Office of the National Coordinator for Health Information Technology Attention: Stephen Posnack Hubert H. Humphrey Building 200 Independence Avenue, SW Suite 729D Washington, DC  20201 Re: Metadata Standards to Support Nationwide Electronic Health Information Exchange Dear Mr. Posnack: On behalf of the American Clinical Laboratory Association (“ACLA”), I am pleased to provide these comments onContinue Reading »...
  • AIM Letter to Sens Murray and Hensarling Regarding IOAS Letter

    September 20, 2011
        September 20, 2011   The Honorable Patty Murray, Co-Chair, Joint Select Committee on Deficit Reduction   The Honorable Jeb Hensarling, Co-Chair, Joint Select Committee on Deficit Reduction   Dear Chairwoman Murray and Chairman Hensarling:   On behalf of the Alliance for Integrity in Medicare (AIM), a coalition committed to ending the practice of inappropriate physician self-referral in Medicare, we recognize the challengesContinue Reading »...
  • Comments Regarding the 2012 PFS Proposed Rule

    August 30, 2011
    August 30, 2011 COMMENTS OF THE AMERICAN CLINICAL LABORATORY ASSOCIATION ON THE MEDICARE PROGRAM; PAYMENT POLICIES UNDER THE PHYSICIAN FEE SCHEDULE AND OTHER REVISIONS TO PART B FOR CY 2012 PROPOSED RULE (CMS-1524-P) The American Clinical Laboratory Association (ACLA) is pleased to have this opportunity to submit our comments on the Medicare Program; Payment Policies under the Physician Fee Schedule and Other Revisions to Part BContinue Reading »...
  • Letter to Joint Deficit Committee Members Regarding Coinsurance

    August 25, 2011
      August 25, 2011 The Honorable Fred Upton Chairman, House Energy and Commerce Committee 2183 Rayburn House Office Building United States House of Representatives Washington, DC 20515 Dear Representative Upton: I am writing you today on behalf of the American Clinical Laboratory Association (ACLA), which represents the leading national, regional, esoteric, pathology and ESRD clinical laboratories. As a member of the Joint Select CommitteeContinue Reading »...
  • Comments on RUO IUO

    August 24, 2011
      August 24, 2011 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville MD 20852 RE: Docket No, FDA-2011-D-0305 Draft Guidance for Industry and FDA Staff: Commercially Distributed In Vitro Diagnostic Products labeled for Research Use Only or Investigational Use Only: Frequently Asked Ouestions Dear Sir or Madam: The American Clinical Laboratory Association (“ACLA”) is pleased to provide commentsContinue Reading »...
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18